This dose-sensitive effect is particularly obvious in Down syndrome-associated AML-SMC3 deficiency that synergizes with GATA1s mutations to promote immature megakaryocyte expansion by activating the Toll-like receptor pathway [70]. Here, SMC3 is linked to acute myeloid leukemia.